Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00524940 · ClinicalTrials.gov registry record · Phase 2
Trial to Describe the Safety and Immunogenicity of Fluzone®
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00524940 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 124 participants.
The verdict
NCT00524940, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
Objective 1:To describe the safety of the inactivated, split-virion influenza vaccine, Northern Hemisphere (NH) 2007-2008 formulation. Objective 2: To describe the immunogenicity, of Fluzone, inactivated, split virion influenza vaccine NH 2007-2008 formulation. Objective 3: Serum Collection - To submit remaining available sera to Center for Biologics Evaluation and research (CBER) for further analysis by the Food and Drug Administration (FDA), the Center for Disease Control and Prevention (CDC), and the World Health Organization (WHO) to support selection and recommendation of antigen strains for subsequent influenza vaccines.
Interventions
- BIOLOGICAL Inactivated, Split-Virion Influenza Virus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00524940
The ClinicalTrials.gov registry entry for NCT00524940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inactivated, Split-Virion Influenza Virus is the first listed.
NCT00524940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00524940 about?
NCT00524940 is a clinical study titled "Trial to Describe the Safety and Immunogenicity of Fluzone®". Objective 1:To describe the safety of the inactivated, split-virion influenza vaccine, Northern Hemisphere (NH) 2007-2008 formulation. Objective 2: To describe the immunogenicity, of Fluzone, inactivated, split virion influenza vaccine NH 2007-2008 formulation. Objective 3: Serum Collection - To s...
What is the current status of trial NCT00524940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2007-08. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00524940?
The interventions under investigation include: Inactivated, Split-Virion Influenza Virus (BIOLOGICAL).
Who is sponsoring clinical trial NCT00524940?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.